ArticleJournal of clinical neurology (Seoul, Korea)2025
Clinical Implications of an Integrated Clinical and Biological Staging Scheme for Alzheimer's Disease.
Article in Journal of clinical neurology (Seoul, Korea), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Beyond Amyloid: Hippocampal Atrophy as a Prognostic Marker in Amyloid-Negative Subjective Cognitive Decline.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Beyond the Amyloid Hypothesis: Systemic Drivers, CNS-PNS Crosstalk, and the Future of Alzheimer's Disease Therapeutics.International journal of molecular sciences · 2026Review
- The Body-First Trajectory: Mapping the Hidden Prologue of Lewy Body Diseases.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Beyond Single Biomarkers: Toward Integrated Staging in Alzheimer's Disease.Journal of clinical neurology (Seoul, Korea) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
background and purposeThis study aimed to characterize the clinical heterogeneity of Alzheimer's disease (AD) by implementing an integrated biological and clinical staging scheme for AD.
methodsClinical staging was performed in 193 participants from the Alzheimer's Disease Neuroimaging Initiative based on cognitive scores, while biological staging was performed based on global tau deposition in tau positron-emission tomography (PET). The discrepancy between clinical and biological stages was quantified as standardized residuals (W-scores), and classified into the following groups: concordant clinical and biological stages (W₀), worse clinical stage (W
resultsRelative to the W₀ group, the W
conclusionsThe integration of clinical and biological staging has significant potential in clinical practice by providing information about copathologies, underlying neurodegeneration, and the progression of AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.